… patients with COVID-19 presenting cytokine release syndrome, thus … IL-6 blockade is
considered a therapeutic target to control cytokine release syndrome (CRS) related to COVID-19…

… (CRS) is a systemic inflammatory disease … by COVID-19 infection during treatment with
nivolumab and ipilimumab. Fever is a common event in cancer patients, especially in COVID-19-…

… ' role in cytokine release syndrome and related manifestations of COVID-19 disease were
reviewed by … Recommendations for the management of cytokine release syndrome and related …

… subgroup of patients with severe COVID-19 might have a cytokine release syndrome. Such
patients have high levels of pro-inflammatory cytokines and chemokines that are associated …

… This cytokine release syndrome (CRS) may occur in up to 70% of patients depending on
conditioning therapy and cell construct, with ICU admission rates up to 13% [[36], [37], [38]]. …

… with control populations identified from landmark trials of ARDS, sepsis, and cytokine
release syndrome. A subanalysis distinguished results in severe versus critical COVID-19. …

… Cytokine release syndrome (CRS) plays a pivotal role in the … of Coronavirus disease-2019
(COVID-19). Therapeutic plasma exchange (TPE) by removing the pathogenic cytokines is …

… Moreover, tocilizumab has been shown to be effective against cytokine release syndrome
resulting from CAR-T cell infusion against B cell acute lymphoblastic leukemia. Blocking anti-…

… in COVID-19 including compromised immunity, worsening coagulopathy, and depletion
of blood bank resources [18]. The cytokine release syndrome is … 20% of COVID-19 cases [19]. …

… for this COVID-19 outbreak. … disease is associated with a high level of release of cytokine
in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome…